The treatment landscape for cutaneous squamous cell carcinoma (CSCC) is evolving, with immunotherapy transforming care across all stages of disease and expanding the role of dermatologists. While surgery and radiotherapy remain cornerstones for localized CSCC, immune checkpoint inhibitors (ICIs) offer durable responses and survival benefits in advanced cases. Emerging approaches, including neoadjuvant, adjuvant, and intralesional ICIs, provide dermatologists with opportunities to integrate these therapies into practice, potentially enhancing surgical outcomes and preserving function in high-risk, resectable CSCC. Preliminary data on anti-PD-1 therapy as a preventive strategy for actinic neoplasia syndrome introduces new avenues for long-term management, though further evidence is needed. As systemic immunotherapy becomes increasingly relevant in dermatology, addressing immunotherapy-related adverse events requires interdisciplinary collaboration and specialized training. These advancements emphasize the expanding responsibilities of dermatologists in CSCC management while highlighting the importance of continued research and thoughtful application of these therapies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00403-025-03933-5 | DOI Listing |
Transl Oncol
March 2025
Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Gansu Urological Clinical Center, Lanzhou, China. Electronic address:
Background: Mesenchymal stem cells (MSCs), due to their tumor-targeting homing properties, are present in the tumor microenvironment (TME) and influence the biological behaviors of tumors. The purpose of this paper is to establish a signature based on the MSC secretome to predict the prognosis and treatment of bladder cancer (BLCA).
Methods: The presence of MSCs in BLCA was validated through flow cytometry and multiplex fluorescence immunohistochemistry (mFIHC), and the relationships between MSCs and clinical characteristics were explored.
Clin Exp Rheumatol
March 2025
Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Objectives: The genetic underpinnings of RA remain partially elucidated, motivating our exploration of copy number variations (CNV) and rare variations in the pathogenesis of RA.
Methods: We conducted an integrated analysis of the genome-wide landscape of CNV and exome-wide rare variation associations with RA in the UK Biobank. To strengthen our findings, we corroborated the results by the differentially expressed genes identified from gene expression profiles of synovial tissue of RA patients and health controls.
J Neurol
March 2025
Centre for Neurology, Department of Neurodegenerative Diseases, and Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.
Next-generation neurostimulators capable of running closed-loop adaptive deep brain stimulation (aDBS) are about to enter the clinical landscape for the treatment of Parkinson's disease. Already promising results using aDBS have been achieved for symptoms such as bradykinesia, rigidity and motor fluctuations. However, the heterogeneity of freezing of gait (FoG) with its wide range of clinical presentations and its exacerbation with cognitive and emotional load make it more difficult to predict and treat.
View Article and Find Full Text PDFDementia (London)
March 2025
Department of Educational Psychology, The University of Texas at Austin, USA.
Parents living with dementia sometimes do not recognize their adult child caregivers, who may then perceive they are forgotten. Yet, research on the experience of being unrecognized and perceived as forgotten by a parent with dementia is scarce. Object relations theory suggests healthy development of a child's sense of self during early development is linked to being held in mind by a primary caretaker.
View Article and Find Full Text PDFCells
March 2025
SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP) Pan African Research Institute (PACRI), University of Pretoria, Hartfield, Pretoria 0028, South Africa.
The peremptory need to circumvent challenges associated with poorly differentiated epithelial endometrial cancers (PDEECs), also known as Type II endometrial cancers (ECs), has prompted therapeutic interrogation of the prototypically intractable and most prevalent gynecological malignancy. PDEECs account for most endometrial cancer-related mortalities due to their aggressive nature, late-stage detection, and poor response to standard therapies. PDEECs are characterized by heterogeneous histopathological features and distinct molecular profiles, and they pose significant clinical challenges due to their propensity for rapid progression.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!